-Reuters
Cartesian Therapeutics Announces Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis
Cartesian Therapeutics, Inc. (NASDAQ:RNAC), ("the Company") a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today announced positive twelve-month follow-up data